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TO THE EDITOR:
Liver transplantation (LT) is plagued by lack of suita-
ble donor organs, and the current waiting list mortal-
ity in the United Kingdom approaches 20%. This
situation remains unchanged despite progressive
expansion of the use of donors previously considered
to be too high risk for transplant. Primary nonfunc-
tion (PNF) in LT recipients remains the main obstacle
to further increasing the use of marginal grafts. The
increasing reliance on marginal extended criteria
donor livers from older donors, with higher body mass
indices or ischemia times is not without consequence.
The potential benefit of using these grafts is often off-
set by post-transplant complications including PNF,
delayed graft function, and ischemia-type biliary stric-
tures that are especially seen in recipients of donation
after cardiac death (DCD) livers.1 Therefore, organ
discard rates have been increasing, most commonly
for degree of graft steatosis, inadequate perfusion, or
prolonged warm and/or cold ischemia time.2
Ischaemia/reperfusion injury is the fundamental
cause of graft damage following static cold storage. The
detrimental effect of cold storage is greatest in marginal
organs, with PNF representing the worst end of the
spectrum of graft dysfunction. The actual risk for a
particular graft is difficult to predict though the reported
incidence for grafts from extended criteria donors,
including those from DCD with cold ischemia time
exceeding 8 hours, could be as high as 30%. Recipients
of DCD grafts are more likely to experience PNF and
delayed graft function, and incidence of ischemia-type
biliary strictures remains a problem.
Over the last decade, machine perfusion technology
has been investigated to improve the quality of mar-
ginal liver grafts based on the encouraging experimen-
tal data and results from the clinical experiences. The
most profound impact of normothermic machine liver
perfusion (NMLP) is derived from this technology’s
unique ability to assess viability during storage.3 On
the basis of our preclinical perfusion experiments on
discarded livers, we developed a viability testing proto-
col for livers deemed not transplantable then subjected
to NMLP. Here, we present the first report of transplan-
tation of a graft salvaged by postischemia NMLP with a
follow-up period of 15 months.
MATERIALS AND METHODS
A liver graft offer from a 29-year-old male DCD donor
was initially accepted for transplantation by our center
within the same allocation region. Withdrawal of life
support was performed in accordance with the UK
standard practice, in the intensive care unit, without
administration of heparin before withdrawal. Oxygen
saturation fell quickly and was not measureable within
minutes of treatment withdrawal, heralding the onset
of donor warm ischemia. However, cardiac death did
not occur until 1 hour and 49 minutes later, and this
exceeded the current UK recommended criteria of liver
graft use from donors with warm ischemia time of <30
minutes. Standard organ procurement followed, how-
ever, using University of Wisconsin perfusion solution
containing heparin. The procuring surgeon described
the graft as a nonsteatotic liver, with soft consistency
and several areas of suboptimal perfusion.
Travel time was estimated to be 4 hours, so the pro-
jected cold ischemia time on arrival at the closest
transplant center was 7 hours. Considering both
extended warm and cold ischemia times, the graft was
therefore deemed not suitable for transplant by our
center and, subsequently, by all other centers upon
allocating as a “fast-tracked” offer. Before the organ
donation, appropriate consent was obtained from the
donor’s family for viability testing of a discarded liver
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using NMLP. The graft was therefore transported to our
center using static cold storage with the aim to resusci-
tate. The cold ischemia time before NMLP was 422
minutes. NMLP commenced with the intent to evaluate
the liver for transplantation into a human, a procedure
which was approved by the Novel Therapeutics Com-
mittee. The predetermined parameters used to assess
viability were monitored by a multidisciplinary team,
and the hospital ethics committee granted an approval
for the procedure.
Perfusion with third-party red cell–based fluid at
37 C using the Liver Assist device (Organ Assist, Gro-
ningen, the Netherlands) was done per protocol. This
perfusion device provides pulsatile flow through the
hepatic artery and nonpulsatile low-pressure flow
through the portal vein. The device has an open cir-
cuit, meaning the hepatic venous outflow drains into
a recirculating reservoir. During the perfusion,
hepatic arterial flow, portal venous flow, perfusate
blood gases, and bile production were assessed every
30 minutes. After only 3 minutes of NMLP, the graft
was pink with homogeneous perfusion (Fig. 1).
The initial arterial and portal venous flow rates were
110 mL/minute and 210 mL/minute, respectively.
Flow rates increased rapidly, reaching 727 mL/minute
in the hepatic artery and 1090 mL/minute in the por-
tal vein after 1.5 hours of NMLP (Fig. 2A). Flow rates
at the end of NMLP were 531 mL/minute for the artery
and 1070 mL/minute for the portal vein. Arterial and
portal venous pressures were maintained within phys-
iological thresholds (Fig. 2B). Resistances in the artery
and portal vein fell as expected and remained low.
The initial reservoir temperature was 20 8C, reaching
35 8C after 34 minutes of NMLP.
The initial lactate of 13.3 mmol/L decreased rapidly
(Fig. 2C). Bile production commenced approximately
30 minutes after the start of perfusion (Fig. 2D). In
total, 27g of bile was excreted. Histologic assessment
demonstrated maintenance of architectural structure
on hematoxylin-eosin staining (Fig. 3A-D). Periodic
acid–Schiff staining highlighted considerable replenish-
ment of hepatocyte glycogen stores from 30% before
NMLP up to 80% after NMLP (Fig. 3E-H). This was
accompanied by a reduction in perfusate glucose
concentration from a maximum of 24.3 mmol/L to
11.4 mmol/L without the administration of exogenous
insulin (data not shown).
In accordance with our protocol for viability testing
and transplantation of discarded liver grafts, the
organ function was assessed by a multidisciplinary
team consisting of 2 transplant surgeons and an
anesthetist, all of whom must agree before proceeding
with transplantation. Our criteria for transplantability
of reconditioned livers are assessed after 2 hours of
warm perfusion. At that time, the lactate must be
below 2 mmol/L, and the graft must be making bile.
After 2 hours of NMLP, the lactate level was 1.2
mmol/L, and bile was being produced; therefore, the
decision was made to transplant the liver.
The selected recipient was a 47-year-old male with
end-stage liver disease from alcohol use complicated by
hepatic encephalopathy. The Model for End-Stage Liver
Disease score was 17. The recipient was informed about
the NMLP resuscitation, graft appearance, and the nov-
elty of the intervention. Informed consent was obtained.
The LT was performed with a vena cava–preserving
(modified piggyback) technique with the creation of a
temporary portocaval shunt. The NMLP continued
throughout the recipient hepatectomy. The graft was
then disconnected from the perfusion device and flushed
with 2 L of histidine tryptophan ketoglutarate solution
(Custodiol, Koehler Chemie, Bensheim, Germany). The
liver was reperfused with an artery-first technique, as is
our protocol with marginal liver grafts. The duration of
NMLP was 416 minutes, and the cumulative time from
the donor aortic cross-clamp to reperfusion in the recipi-
ent was 13 hours and 58 minutes.
RESULTS
There was no evidence of postreperfusion syndrome or
fibrinolysis. The total operative time was 5 hours and 3
minutes, and the recipient required 5 units of packed
red cells and 6 units of fresh frozen plasma. The
patient’s recovery was uneventful. The peak posttrans-
plant alanine aminotransferase (ALT) was 1215 IU/L, on
the first postoperative day, and the creatinine remained
in the physiologic range (Fig. 4A,B, respectively). The
Figure 1. The liver graft on NMLP. (A) The patchy perfused graft after cold preservation and (B) homogeneously perfused liver graft
perfused with NMLP.
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patient was discharged home on postoperative day 10.
Since the first postoperative month, his aspartate
aminotransferase (AST), ALT, bilirubin, and alkaline
phosphatase (ALP) have remained normal. Per study
protocol, the recipient underwent magnetic resonance
cholangiopancreatography (MRCP) at 6 months after
the transplantation, which showed a mild anastomotic
biliary narrowing that has remained clinically silent (Fig.
4C). With 15 months of follow-up, the recipient has nor-
mal liver and kidney function, without any evidence of
intrahepatic biliary ischemia.
DISCUSSION
We present the world’s first case of successful normo-
thermic resuscitation of a liver graft initially deemed
too high risk that was rejected for transplantation. We
aim to highlight the innovation this new technique
presents, and the profound impact it could have on
organ utilization.
Liver viability testing may transform the graft selec-
tion by providing objective assessment of graft func-
tion after procurement. The acceptance criteria for
organ usage vary widely among regions depending
largely on the local organ availability and waiting-list
mortality. The ability to use extended criteria liver
grafts in the United Kingdom is significant because of
the center-based liver allocation system. This alloca-
tion system allows the matching of high-risk organs
to low-risk recipients. Applying NMLP technology for
viability testing of marginal grafts could finally allow
real-time assessment of objective data about liver
function. In the United Kingdom, there is potential to
increase graft availability by 10%-15% by incorporat-
ing such an approach.
Temperature is the principal factor distinguishing
different machine perfusion techniques, and the way
these techniques can best be implemented in the clin-
ical setting is yet to be defined. Liver perfusion was
pioneered by Guarrera et al.,4 who recently published
the results of a series of patients transplanted with
very marginal grafts preserved by hypothermic perfu-
sion with successful outcomes with low incidence of
PNF (3%) and early allograft dysfunction. In parallel,
the Zurich group introduced into clinical practice
hypothermic oxygenated machine perfusion.5 The
advantage of cold perfusion is its simplicity and
resultant low risk of device failure–related graft loss.
NMLP is technically more challenging, and therefore,
carries a small risk of graft loss related to the device
malfunction. The overwhelming advantage of NMLP is
that it is the only machine perfusion technique that
can evaluate graft viability and provide a real-time
indication of the organ transplantability.
The presented 15-month follow-up data might be
too short to eliminate the presence of asymptomatic
nonanastomotic biliary strictures, which can occur in
DCD grafts that may present very late.1 The presented
Figure 2. Monitoring liver graft during the normothermic resuscitation using mechanistic parameters and lactate clearance/bile pro-
duction. (A) Flow parameters, hepatic artery flow (red) and portal vein flow (blue). (B) Hepatic artery pressure (red), hepatic artery
resistance (yellow), portal vein pressure (blue), and portal vein resistance (green). (C) Lactate concentration in the arterial end of the
circuit. (D) Cumulative bile production.
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patient’s case highlights the potential benefits of
NMLP, though these need to be validated by
adequately powered clinical trials.
The patient’s safety is of paramount importance
when physicians introduce a novel technique to the
clinical practice. In our unit, the viability testing pro-
tocol and the institutional project approval was
granted for a small, closely monitored recipient series
of carefully selected discarded grafts. We considered a
nonsteatotic DCD graft from a young donor to be an
acceptable risk–benefit balance for the first clinical
use of this technique. Furthermore, our group was
also involved in the first human safety and feasibility
study of continuous NMLP (ORGANOX study; in
press) and currently a major contributor to the
randomized European multicenter trial investigating
the benefits of continued NMLP versus static cold
preservation (consortium of organ preservation in
Europe [COPE] trial). The procedure described herein
was performed in the background of this experience;
undoubtedly such experience helped us in this
approach.
In conclusion, this first report proves the clinical
feasibility of liver viability testing by NMLP on a liver
that was deemed unsuitable for transplant by all the
centers in the United Kingdom. With the progressive
graft shortage and increasing waiting-list mortality,
this technique may revolutionize the use of extended
criteria grafts by providing objective functional
parameters in real-time during storage to determine
transplantability. NMLP may salvage discarded grafts,
and minimize the risk of early graft dysfunction and
PNF when transplanting marginal livers. Although the
recipient in this case has excellent liver function at 10
Figure 3. Histology from 16-gauge biopsy samples. (A-F) Before the NMLP and (G-L) at the end of NMLP but before implantation.
(A,D,G,J) Hematoxylin-eosin staining to demonstrate tissue architecture; (B,E,H,K) periodic acid–Schiff staining to detect polysaccha-
ride content, including glycogen stores; (C,F,I,L) complement degradation product 4d immunostaining to demonstrate necrotic hepato-
cytes. (A-C, G-I) At 3 10 magnification; (D-F, J-L) at 3 40 magnification.
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months, a prospective randomized trial is warranted
to better define longterm outcomes and effects on
organ utilization rates.
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